Eli Lilly & Co.'s SEC filings document the regulatory record for its pharmaceutical business, listed common stock and NYSE-traded notes. Forms 8-K report operating results and financial condition, annual meeting vote outcomes, director and officer matters, underwriting agreements and other material events tied to the company's capital structure and governance.
Proxy filings provide formal disclosure on board elections, executive compensation, shareholder voting matters and pay-versus-performance information. The company's exchange-listed securities include no-par common stock under LLY and multiple series of notes with maturities extending across its debt capital structure.
Patrik Jonsson, EVP & President, LLY Int'l, reported a bona fide gift of 704 shares of Eli Lilly & Co common stock on November 10, 2026. He reported 53,442.62 shares held directly following the transfer; the report also lists 632.72 shares held indirectly through a 401(k).
Eli Lilly & Co. President, Chair, and CEO David A. Ricks reported a gift disposition of 23,538 common shares on November 3, 2026; his direct holdings afterward were 555,278 shares. No Rule 10b5-1 plan is reported. The November 3 holdings also list 4,574 shares in his 2025 GRAT, 49,127 in his 2022 GRAT, 300 in a trust, 68,656 in his SLAT, and 7,338 in a 401(k). Ricks disclaims beneficial ownership of securities in the GRAT, trust, and SLAT entries except to the extent of his pecuniary interest.
Eli Lilly & Co. EVP, CS&PO & Pres. LRL Daniel Skovronsky reported a bona fide gift disposition of 119 common shares on November 2, 2026; no Rule 10b5-1 plan is reported. His reported direct holdings after the transfer were 159,953 shares. The report also lists indirect holdings as of November 2, 2026: 72,359 shares by trust, 547 by spouse, and 2,710 by spouse’s SLAT. A footnote attached to those indirect holdings says he disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Eli Lilly & Co. (LLY) reported an indirect sale by the spouse of Anat Hakim, its EVP, GC & Secretary: 5,000 common shares at $1,402.52 per share on November 2, 2026, under a Rule 10b5-1 trading plan adopted February 10, 2026. The reported spouse-held balance after the sale was 4,137 shares. Separate entries list 25,725 directly held shares, reflecting a net transfer of 2,738 shares from the spouse, and 15,700 shares held indirectly by Anat Hakim SLAT.
Eli Lilly EVP & CFO Lucas Montarce converted 1,610 restricted stock units into 1,610 common shares on November 1, 2026. Each unit represents a contingent right to receive one common share, and the reported restricted-stock-unit position was 0 after conversion. On the same date, 678 common shares were delivered or withheld for payment of exercise price or tax liability, at a reported price of $1,417.54 per share.
Eli Lilly & Co. EVP & President, Manufacturing Operations Edgardo Hernandez exercised 2,530 restricted stock units on November 1, 2026, acquiring 2,530 common shares; each unit represents a contingent right to receive one common share. On the same date, 1,122.902 common shares were delivered or withheld for payment of exercise price or tax liability. The restricted-stock-unit position following the transaction was zero. Hernandez also reported 874.6 common shares held indirectly through a 401(k) as of November 1, 2026.
Eli Lilly & Co reported that Eric Dozier, EVP, Chief People Officer, exercised 2,300 restricted stock units on November 1, 2026, acquiring 2,300 common shares; each unit represents a contingent right to one common share. He also delivered or had withheld 1,019 common shares for payment of exercise price or tax liability. The derivative position following the transaction was 0 restricted stock units; an indirect 401(k) holding lists 414 common shares as of November 1, 2026. No Rule 10b5-1 plan is reported.
Eli Lilly & Co. EVP & President, Card Met Hlth Kenneth L. Custer exercised 3,220 restricted stock units on November 1, 2026, and acquired 3,220 shares of common stock. On the same date, 1,425 shares were delivered or withheld for payment of exercise price or tax liability, at a reported price of $1,417.54 per share. The reported restricted stock unit position following the exercise was 0.
At Eli Lilly & Co., Adrienne S. Brown, EVP, President LLY Imm, exercised 2,530 restricted stock units into 2,530 common shares on November 1, 2026. On that date, 1,099 common shares were delivered or withheld for payment of exercise price or tax liability; the reported price was $1,417.54 per share. No Rule 10b5-1 plan is reported for the transaction.
Lilly Endowment, Inc., identified as a shareholder, gave notice of its intended sale of 295,000 Eli Lilly and Company common shares, with an aggregate market value of $405,241,500. J.P. Morgan Securities LLC is identified as the broker, and October 30, 2026, as the approximate sale date.
The notice also lists five earlier sales by Lilly Endowment from August 13 through October 15, 2026. Peter A. Buck, Vice President for Investments & Grants Administration, signed the notice.